Fremont migraine patch developer Zosano sold in bankruptcy court for $1M


The FDA rejected the company's migraine patch twice and a biopharma investing downturn made it difficult to raise more money.

Previous Athersys plans reverse stock split by Monday's market opening
Next As Idaho abortion ban to take effect, leaders vow to support those seeking services in Oregon